NCT01031381 - Study of RAD001 and Bevacizumab in Recurrent Ovarian, Peritoneal, and Fallopian Tube Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 30, 2010

Primary Completion Date

January 31, 2014

Study Completion Date

December 31, 2014

Conditions

Ovarian CancerFallopian Tube CancerPrimary Peritoneal Carcinoma

Interventions

DRUG

RAD001

RAD001 10mg is taken orally (by mouth) once daily on a continuous basis. RAD001 is provided in tablet form and should be taken with a big glass of water on an empty stomach or after a low-fat meal.

DRUG

bevacizumab

bevacizumab will be administered intravenously (IV) once every 14 days.

Trial Locations (1)

15213

Magee-Womens Hospital of UPMC, Pittsburgh